General form of registration statement for all companies including face-amount certificate companies

Note 9 - Stockholders' Equity 1 (Details Textual)

v3.24.4
Note 9 - Stockholders' Equity 1 (Details Textual)
$ / shares in Units, $ in Millions
 1 Months Ended 9 Months Ended 12 Months Ended
Jul. 23, 2024
$ / shares
shares
May 20, 2021
$ / shares
shares
Apr. 01, 2020
shares
Jan. 30, 2019
shares
Jun. 01, 2016
USD ($)
shares
Dec. 31, 2022
$ / shares
shares
Nov. 30, 2022
USD ($)
Aug. 31, 2021
USD ($)
$ / shares
Nov. 30, 2019
USD ($)
$ / shares
shares
Sep. 30, 2024
$ / shares
shares
Sep. 30, 2023
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Nov. 01, 2019
$ / shares
Jun. 30, 2016
$ / shares
Common Stock, Shares Authorized (in shares)           29,000,000       29,000,000   29,000,000 29,000,000    
Common Stock, Shares, Issued (in shares)           5,720,009       5,720,009   5,720,009 5,720,009    
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares           $ 0.00001       $ 0.00001   $ 0.00001 $ 0.00001    
Preferred Stock, Shares Authorized (in shares)                   20,655,895   20,655,895      
Series B Preferred Stock [Member]                              
Preferred Stock, Shares Authorized (in shares)                   1,533,528   1,533,528      
Preferred Stock, Shares Outstanding, Ending Balance (in shares)                   1,533,528   1,533,528      
Shares Issued, Price Per Share (in dollars per share) | $ / shares                   $ 3.19   $ 3.19      
Series C Preferred Stock [Member]                              
Preferred Stock, Shares Authorized (in shares)                   8,509,995   8,509,995      
Preferred Stock, Shares Outstanding, Ending Balance (in shares)                   8,509,995   8,509,995      
Shares Issued, Price Per Share (in dollars per share) | $ / shares           5.29       $ 5.29   $ 5.29 5.29    
Series D Preferred Stock [Member]                              
Preferred Stock, Shares Authorized (in shares)                   7,130,335   7,130,335      
Preferred Stock, Shares Outstanding, Ending Balance (in shares)                   1,835,227   1,835,227      
Shares Issued, Price Per Share (in dollars per share) | $ / shares           $ 5.29       $ 5.29   $ 5.29 $ 5.29    
Stock Issued During Period, Shares, New Issues (in shares)           1,835,227                  
Series D Preferred Stock [Member] | Common Stock [Member]                              
Stock Issued During Period, Shares, New Issues (in shares)                         0    
Series D Preferred Stock [Member] | Preferred Stock [Member]                              
Stock Issued During Period, Shares, New Issues (in shares)                         1,835,227    
Pieris Pharmaceuticals, Inc. [Member]                              
Common Stock, Shares Authorized (in shares)           3,750,000       3,750,000   3,750,000 3,750,000    
Common Stock, Shares, Issued (in shares)           931,489       1,320,240   1,236,688 931,489    
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares           $ 0.001       $ 0.001   $ 0.001 $ 0.001    
Preferred Stock, Shares Authorized (in shares)           10,000,000       10,000,000   10,000,000 10,000,000    
Preferred Stock, Shares Issued (in shares)           15,617       15,618   15,617 15,617    
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares           $ 0.001       $ 0.001   $ 0.001 $ 0.001    
Preferred Stock, Shares Outstanding, Ending Balance (in shares)           15,617       15,618   15,617 15,617    
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)                   13.34          
Pieris Pharmaceuticals, Inc. [Member] | Conversion of Common Stock into Series E Preferred Stock [Member]                              
Sale of Stock, Number of Shares Issued in Transaction (in shares)     3,000                        
Conversion of Stock, Shares Converted (in shares)   62,500 37,500                        
Conversion of Stock, Shares Issued (in shares)   5,000                          
Pieris Pharmaceuticals, Inc. [Member] | Securities Purchase Agreement [Member]                              
Preferred Stock, Shares Issued (in shares)         4,963                    
Partners' Capital Account, Units, Sold in Private Placement (in shares)         8,188,804                    
Shares Issued, Price Per Share (in dollars per share) | $ / shares $ 13.7299                           $ 2.015
Proceeds from Issuance of Private Placement | $         $ 16.5                    
Proceeds From Issuance Of Private Placement Net | $         $ 15.3                    
Sale of Stock, Number of Shares Issued in Transaction (in shares)       62,500 40,323                    
Stock Issued During Period, Shares, New Issues (in shares) 3,154,241                            
Pieris Pharmaceuticals, Inc. [Member] | At the Market Offering [Member] | Jefferies L L C [Member]                              
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares               $ 0.001              
Shares Issued, Price Per Share (in dollars per share) | $ / shares           $ 276.51         $ 0.84 $ 67.07 $ 276.51    
Sale of Stock, Authorized Amount | $             $ 75.0 $ 50.0              
Stock Issued During Period, Shares, New Issues (in shares)                   0 24,300,000 0.3 25,000    
Stock Issued During Period, Value, Issued for Services | $                       $ 20.3 $ 7.2    
Pieris Pharmaceuticals, Inc. [Member] | Common Stock [Member]                              
Number Of Votes Per Share                       1      
Stock Issued During Period, Shares, New Issues (in shares)                     303,000 304,000 25,000    
Pieris Pharmaceuticals, Inc. [Member] | Preferred Stock [Member]                              
Stock Issued During Period, Shares, New Issues (in shares)                     0 0 0    
Pieris Pharmaceuticals, Inc. [Member] | Preferred Stock [Member] | Preferred Share Exchange [Member]                              
Sale of Stock, Number of Shares Issued in Transaction (in shares)       5,000                      
Pieris Pharmaceuticals, Inc. [Member] | Series A Preferred Stock [Member]                              
Preferred Stock, Shares Issued (in shares)           85       85   85 85    
Preferred Stock, Shares Outstanding, Ending Balance (in shares)           85       85   85 85    
Pieris Pharmaceuticals, Inc. [Member] | Series B Preferred Stock [Member]                              
Preferred Stock, Shares Issued (in shares)           4,026       4,026   4,026 4,026    
Preferred Stock, Shares Outstanding, Ending Balance (in shares)           4,026       4,026   4,026 4,026    
Pieris Pharmaceuticals, Inc. [Member] | Series C Preferred Stock [Member]                              
Preferred Stock, Shares Issued (in shares)           3,506       3,506   3,506 3,506    
Preferred Stock, Shares Outstanding, Ending Balance (in shares)           3,506       3,506   3,506 3,506    
Pieris Pharmaceuticals, Inc. [Member] | Series C Preferred Stock [Member] | Preferred Share Exchange [Member]                              
Sale of Stock, Price Per Share (in dollars per share) | $ / shares                           $ 274.4  
Debt Instrument, Convertible, Beneficial Conversion Feature | $                 $ 2.8            
Pieris Pharmaceuticals, Inc. [Member] | Series C Preferred Stock [Member] | Private Placement [Member]                              
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)                 0.001            
Proceeds From Issuance Of Private Placement Net | $                 $ 31.0            
Sale of Stock, Number of Shares Issued in Transaction (in shares)                 9,014,960            
Sale of Stock, Price Per Share (in dollars per share) | $ / shares                 $ 3.55            
Sale of Stock, Consideration Received Per Transaction | $                 $ 32.0            
Stock Issued During Period, Shares, Conversion of Units (in shares)                 1            
Sale of Stock, Number of Warrants, Per Unit (in shares)                 1            
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)                 1            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares                 $ 568            
Convertible Preferred Stock, Weighted Average Stock Price, Percent                 3.00%            
Pieris Pharmaceuticals, Inc. [Member] | Series C Preferred Stock [Member] | Private Placement [Member] | Maximum [Member]                              
Warrants and Rights Outstanding, Term (Year)                 5 years            
Pieris Pharmaceuticals, Inc. [Member] | Series D Preferred Stock [Member]                              
Preferred Stock, Shares Issued (in shares)           3,000       3,000   3,000 3,000    
Preferred Stock, Shares Outstanding, Ending Balance (in shares)           3,000       3,000   3,000 3,000    
Pieris Pharmaceuticals, Inc. [Member] | Series E Preferred Stock [Member]                              
Preferred Stock, Shares Issued (in shares)           5,000       5,000   5,000 5,000    
Preferred Stock, Shares Outstanding, Ending Balance (in shares)           5,000       5,000   5,000 5,000    
Pieris Pharmaceuticals, Inc. [Member] | Series A Through E [Member] | Preferred Stock [Member]                              
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares   $ 0.001                          
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)   13.34                          
Convertible Preferred Stock, Common Stock Ownership Limit, Percent   9.99%                          
Convertible Preferred Stock, Beneficial Ownership Limitation, Percent   19.99%                          
Convertible Preferred Stock, Beneficial Ownership Limitation, Notice Period Before Increase (Year)   61 years